<DOC>
	<DOCNO>NCT00324506</DOCNO>
	<brief_summary>The primary objective safety/mechanistic study determine safety tolerability oral Cellcept compare weekly intramuscular Avonex relapse multiple sclerosis . Safety assess virtue change size number lesion MRI scan .</brief_summary>
	<brief_title>Safety Efficacy Cellcept Avonex Combination Treatment Multiple Sclerosis</brief_title>
	<detailed_description>Sixty patient ( 20 patient recruit center ) RR MS satisfy inclusion exclusion criterion treat CellCept® Avonex® first 6 month study . Those patient fifty-fifty chance receive either Avonex Cellcept . Baseline data collect treatment begin include MRIs , chest x-ray , EKG , standard labwork , along blood test HIV Hepatitis B . Once enrol , study visit include periodic MRI scan , neurological exam examine neurologist every three month , frequent bloodwork , questionnaire , eye-testing month zero , six , twelve month . Eye test take one hour require dilation pupil . All assessment standard care ophthalmology exception optical coherence tomography ( OCT ) -- non-invasive procedural device record graphical numerical measurement optic nerve macula . All patient begin active combination therapy CellCept® Avonex® second 6 month study . During second phase , MRI clinical examination perform .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Patient diagnose clinically definite MS accord McDonald criterion # 1 # 4 Age 1855 Have RR disease course Have EDSS score less equal 5.0 Have disease duration one day 20 year Have least one medically documented clinical relapse within 12 month prior randomization ( eligibility , prestudy relapse define neurologic symptom sign document review history subject medical record , sufficient severity duration determine investigator consistent acute MS relapse ; relapse need treat qualify ) and/or progression ≥1.0 point EDSS previous year Have ≥1 Gdenhancing brain lesion monthly runin baseline MRI ≥2 T2 brain lesion consistent MS screen scan Signed inform consent None exclusion criterion Previous treatment 3 month prior study entry standard diseasemodifying therapy ( interferonbeta glatiramer acetate , IVIG plasmaphoresis ) . Previous treatment 12 month prior study entry immunosuppressant agent , e.g. , mitoxantrone , cyclophosphamide , cladribine , fludarabine , cyclosporine total body irradiation concomitant immunomodulatory therapy ( e.g. , azathioprine , methotrexate , , CellCept® , natalizumab , immunomodulators/monoclonal agent ) . Patients receive steroid treatment 30 day prior MRI scan date Women pregnant , lactate childbearing age consent approve contraceptive use study . Abnormal blood test , perform screen visit ( see adverse event section )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>